Schaefer R M, Kokot F, Kuerner B, Zech M, Heidland A
Department of Internal Medicine, University of Weurzburg, FRG.
Int J Artif Organs. 1989 Jul;12(7):445-9.
Correction of anemia in long-term hemodialysis patients by recombinant human erythropoietin (r-HuEPO) has been reported to improve sexual function. As elevated serum prolactin levels are believed to contribute to altered sexual function in uremia, we followed serum prolactin and testosterone levels during four months of r-HuEPO therapy. Within these four months, hematocrit values rose from 23.7 +/- 1.2 to 35.7 +/- 0.2% and hemoglobin from 7.3 +/- 0.3 to 11.3 +/- 0.4 g/100 ml. In parallel, serum prolactin values decreased significantly, from 66.9 +/- 9.3 to 9.6 +/- 2.6 ng/ml in females and from 39.5 +/- 10.5 to 10.3 +/- 1.0 ng/ml in male dialysis patients. Testosterone concentrations were in the lower normal range in male patients and remained unchanged during r-HuEPO therapy. Sexual function improved in four out of seven males, and five out of nine female patients started to have regular menstruations again. It appears that treatment of anemia in end-stage renal disease by r-HuEPO may improve sexual function by lowering elevated serum prolactin concentrations.
据报道，重组人促红细胞生成素（r-HuEPO）纠正长期血液透析患者的贫血可改善性功能。由于血清催乳素水平升高被认为与尿毒症患者性功能改变有关，我们在r-HuEPO治疗的四个月期间监测了血清催乳素和睾酮水平。在这四个月内，血细胞比容值从23.7±1.2升至35.7±0.2%，血红蛋白从7.3±0.3升至11.3±0.4 g/100 ml。同时，血清催乳素值显著下降，女性透析患者从66.9±9.3降至9.6±2.6 ng/ml，男性透析患者从39.5±10.5降至10.3±1.0 ng/ml。男性患者的睾酮浓度处于正常范围下限，在r-HuEPO治疗期间保持不变。7名男性中有4名性功能改善，9名女性患者中有5名再次开始规律月经。看来，r-HuEPO治疗终末期肾病贫血可能通过降低升高的血清催乳素浓度来改善性功能。
